Global Opioid-Induced Respiratory Depression Market Size study, By Product Type (Pulse Oximeter, Capnographs, Audiometry, Integrated Delivery & Monitoring Devices, Acoustic Monitor, Radar Monitor, Bioimpedance Device, Inductance Plethysmograph), By End User (Hospital, Ambulatory Surgical Center, Specialty Clinic, Diagnostic Center, Others), and Regional Forecasts 2022-2028Global Opioid-Induced Respiratory Depression Market is valued approximately USD XX million in 2021 and is anticipated to grow with a healthy growth rate of more than XX % over the forecast period 2022-2028. Opioid-Induced Respiratory Depression can be defined as breathing difficulties caused due to overdose of opioids. Opioids are a class of drugs that include the illegal drug heroin, synthetic opioids such as fentanyl, and pain relievers available legally by prescription, such as oxycodone, hydrocodone, codeine, morphine etc. The rising incidences of opioid use and drug overdose and increasing prevalence of hypoventilation syndrome as well as recent product launches and favorable government policies are accelerating the global market demand. For instance, according to World Health Organization – as of 2021, Worldwide drug use caused 500,000 deaths. More than 70% of these deaths are caused due to opioids, whereas 30% of deaths caused by overdose of opioids. Furthermore, In August 2021, FDA approved use of higher dose naloxone hydrochloride nasal spray for treatment of opioid overdose. Moreover, In December 2021, Switzerland based Sandoz launched authorized generic version of Narcan®(naloxone hydrochloride) Nasal Spray in United States. This new drug is intended to reverse opioid overdose. This spay would be available through retail pharmacies and hospitals . Also, growing number of rehabilitation activities and rising R&D activities towards development of new therapeutics solutions are anticipated to act as a catalyzing factor for the market demand during the forecast period. However, high treatment cost associated with respiratory depression impede the growth of the market over the forecast period of 2022-2028.
The key regions considered for the global Opioid-Induced Respiratory Depression Market study include Asia Pacific, North America, Europe, Latin America, and the Rest of the World. North America is the leading region across the world in terms of market share owing to the growing prevalence of opioid-induced respiratory depression and presence of leading market players. Whereas, Asia Pacific is anticipated to exhibit a significant growth rate over the forecast period 2022-2028. Factors such as rising pharmaceuticals sector and increasing number of rehabilitation centers in the region, would create lucrative growth prospects for the Opioid-Induced Respiratory Depression Market across the Asia Pacific region.
Major market players included in this report are:
Medtronic plc
Smiths Group
Masimo Corporation
Nihon Kohden Corporation
Covidien, GE Healthcare
Welch Allyn
Becton
Dickinson and Company
BioMed Jena GmbH
Hill-Rom, Inc.
The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming eight years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within each of the regions and countries involved in the study. Furthermore, the report also caters the detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, the report shall also incorporate available opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below:
By Product Type
Pulse Oximeter
Capnographs
Audiometry
Integrated Delivery & Monitoring Devices
Acoustic Monitor
Radar Monitor
Bioimpedance Device
Inductance Plethysmograph
By End User
Hospital
Ambulatory Surgical Center
Specialty Clinic
Diagnostic Center
Others
By Region:
North America
U.S.
Canada
Europe
UK
Germany
France
Spain
Italy
ROE
Asia Pacific
China
India
Japan
Australia
South Korea
RoAPAC
Latin America
Brazil
Mexico
Rest of the World
Furthermore, years considered for the study are as follows:
Historical year – 2018, 2019, 2020
Base year – 2021
Forecast period – 2022 to 2028
Target Audience of the Global Opioid-Induced Respiratory Depression Market in Market Study:
Key Consulting Companies & Advisors
Large, medium-sized, and small enterprises
Venture capitalists
Value-Added Resellers (VARs)
Third-party knowledge providers
Investment bankers
Investors
Companies Mentioned
Medtronic plc
Smiths Group
Masimo Corporation
Nihon Kohden Corporation
Covidien, GE Healthcare
Welch Allyn
Becton
Dickinson and Company
BioMed Jena GmbH
Hill-Rom, Inc.
Please note:The single user license is non-downloadable and non-printable. Global Site license allows these actions.
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook